RxDoctor Payments Data

Scott Salomone, MD

Psychiatry · Murray, UTNPI 1386178481

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 26.4% of the total. 2025 is the largest year on record at $1,373, 6.4 times the $215 reported in 2021. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,355in general payments, 2019–2025

Across 220 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$635
  • Johnson & Johnson$615
  • Neurocrine Biosciences, Inc.$566
  • Axsome Therapeutics, Inc.$261
  • Lundbeck LLC$212
  • plus $916 from 11 others

What the payments were for

  • Food & beverage$4,25398%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,355 in reported general payments places this provider in the 90th percentile of 231 psychiatry providers in Utah.

See all psychiatry providers in Utah

Medicare billing

Part B allowed, 2024
$16,184
Medicare patients
21
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl30$47,602
VraylarCariprazine Hcl14$20,538
Haloperidol Decanoate19$1,143
Quetiapine Fumarate48$952
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$775
Duloxetine Hcl23$634
Aripiprazole28$611
Lamotrigine23$478
Propranolol Hcl28$467
Fluoxetine Hcl44$461
Bupropion Hcl SrBupropion Hcl26$450
Bupropion XlBupropion Hcl13$450
Divalproex Sodium ErDivalproex Sodium13$437
Gabapentin18$323
Donepezil Hcl17$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$615$47,60230 claims
AbbVieVraylar$1,151$20,53814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 psychiatry providers in Utah.

Other psychiatry in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →